- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02417506
Study to Assess the Effect of E-OA-07 on Acute Pain Response in Subjects Suffering From Knee OA (Osteolanc)
A Double Blind Randomized Comparator Controlled Study to Assess the Effect of E-OA-07 (Lanconone) on Acute Pain Response in Subjects Suffering From Osteoarthritis of the Knee
The repetitive motions associated with active life and many sports can increase the wear and tear to the joints that leads to decrease in flexibility and joint pain finally heading its way to osteoarthritis. Activities such as jumping, running can wear away the cartilage that supports and cushions the joints of hands and knees, causing bones to rub against each other. Injuries stemming from repetitive motions can also cause and worsen the joint pain.
Joint pain is discomfort that arises from any joint . Irrespective of the underlying mechanisms, joint pain usually originates in activation of nociceptors, or free nerve endings. Complex neuronal activation occurs, which involves not only local sensitization of joint nociceptors but also modifications in central pain pathways.
Even though, the numerous pharmacological interventions are available for joint pain, there is much debate amongst clinicians about the best approach to the treatment of joint pain. NSAIDs which is frequently used for treatment in such cases, carries concerns related to gastro-intestinal system, cardiovascular system as well as central nervous system .
Hence there is a need of a safer alternative treatment option for relieving acute joint pain which is comparable to the modern medicines, without posing concerns to the subject's general well being.
Herbs are known to be used since ages in traditional literature and do not pose any potential health concern. Inspite of such positive attributes herbs are not employed in treatment of acute pains as there is lack of evidence proving the same.
In order to address the need of the hour Enovate Biolife has invented a novel poly herbal formulation E-OA-07 (Lanconone). Lanconone has been studied previously in patients with osteoarthritis has been proven efficacious . It has a good history of marketing and is sold in the United States, with no reported adverse event related to the product. However there is no concrete evidence proving the product's acute pain relieving dynamics, hence the current study has been employed to comprehend the effect of lanconone in joint acute pain.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400059
- Mukund Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ambulatory adults of either sex aged 40 to 60 years.
- Subjects with moderate OA of the knee, which can be clinically, categorized as ARA functional Class II and III with radiological confirmation of Kellgren Lawrence Grade II and III. (incase of bilateral OA, the knee with the more severe symptoms will be defined as index joint)
- Subjects with OA in a flare state at the baseline defined by one of following category of flare:
In subjects who have been receiving non steroidal anti-inflammatory drugs (NSAIDs) or analgesic therapy for their OA, flare will be defined as having at least two of the following three criteria while comparing screening to baseline:
- Subject's assessment of arthritis pain VAS walking on a flat surface at baseline of ≥ 40 mm;
- Increase of ≥ 1 grade in the patients global assessment of arthritis;
- Increase of ≥ 1 grade in the physician's global assessment of arthritis;
In subjects who are not receiving NSAID or analgesic therapy , an OA flare state will be defined as having at least two of the following three criteria
- Subject's assessment of arthritis pain VAS walking on a flat surface at baseline of ≥ 40 mm
- Patient's global assessment of arthritis of ''poor''; very poor
- Physician's global assessment of arthritis of ''poor''; very poor
Exclusion Criteria:
- Subjects with any form of arthritis other than osteoarthritis.
- Administration of intra-articular or oral steroids in the past 3 month or intra articular hyaluronic acid in the last 9 months or parenteral use of NSAIDs
- History of major chronic hepatic, cardiovascular, neurological or immunosuppressive conditions or the presence of any infections
- Subjects with localized trauma to the lower limb
- Had received oral, intramuscular, or intra-articular corticosteroids within 8 weeks, or intra-articular hyaluronic acid in the index joint within 6 months of study drug administration;
- Subjects on nutritional supplement or herbal product since last one month
- Subjects otherwise judged by the investigator to be inappropriate for inclusion in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E-OA-07 (Lanconone)
500 mg two capsules to be taken stat at the site
|
Other Names:
|
Active Comparator: Ibuprofen
200 mg two capsule to be taken stat at the site
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain score as measured by Visual Analogue Scale
Time Frame: Day 0
|
Day 0
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Shalini Srivastava, M.D.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Acute Pain
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
- EB/ 140501 /LC/ OA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of Knee
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
CrystalGenomics, Inc.CompletedLocalized Primary Osteoarthritis of Hip | Localized Primary Osteoarthritis of KneeKorea, Republic of
-
Ottawa Hospital Research InstituteCompleted
-
zhoupingBeijing Friendship Hospital; Beijing Jishuitan HospitalUnknownOsteoarthritis Of KneeChina
-
Universidade Nova de LisboaHospital de Santa Maria, Portugal; NOVA Medical School; Hospital de Egas Moniz; Instituto de Medicina Molecular João Lobo Antunes and other collaboratorsUnknown
-
Hospices Civils de LyonSmith & Nephew, Inc.Completed
-
First Affiliated Hospital of Harbin Medical UniversityShanghai Baiying Medical Technology Co., Ltd.UnknownOsteoarthritis Of KneeChina
-
Stempeutics Research Pvt LtdStempeutics Research Malaysia SDN BHDCompleted
-
Government Medical College, BhavnagarCompletedOsteoarthritis of Knee JointIndia
-
Barbara A RakelCompletedUnilateral Primary Osteoarthritis of Knee | Primary Osteoarthritis of Knee NosUnited States
Clinical Trials on Ibuprofen
-
Reckitt Benckiser Healthcare (UK) LimitedPremier Research Group plcCompletedStomatognathic Diseases | Tooth Diseases | Tooth, ImpactedUnited States
-
Reckitt Benckiser Healthcare (UK) LimitedTerminated
-
Reckitt Benckiser Healthcare (UK) LimitedSimbec ResearchCompletedHealthy Volunteer Study
-
Overseas Pharmaceuticals, Ltd.Virginia Contract Research Organization Co., Ltd.Terminated
-
Fundacion para la Investigacion Biomedica del Hospital...CompletedPatent Ductus ArteriosusSpain
-
Darnitsa Pharmaceutical CompanyACDIMA BiocenterCompletedHealthy Subjects | BioequivalenceJordan
-
Pierre Fabre MedicamentCompleted
-
Indonesia UniversityCompleted
-
SocraTec R&D GmbHSocraMetrics GmbHCompleted